The DOI matches its Crossref record.
Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.
Open accessAbstract
We evaluated an elderly patient with a lifelong history of severe bleeding after surgery or trauma and with evidence of persistent hyperfibrinolysis. Routine coagulation studies were normal. Serum plasminogen (40%, normal 72-128%) and alpha 2-antiplasmin (55%, normal 70-145%) activities were decreased. Euglobulin clot lysis was abnormally shortened (50 min) and normalized in vitro with epsilon-aminocaproic acid (EACA). The patient was treated with EACA with prompt cessation of bleeding. Patient tissue-plasminogen activator (t-PA) levels in serum were normal (4.7 ng/ml, control 3.5-7.2) as detected by a two-site immunoradiometric assay (IRMA). Patient fibrinolytic inhibitor activities were assessed by incubating 125I-labeled t-PA with either whole blood or serum followed by SDS-PAGE and autoradiography to identify the resultant protease/protease inhibitor complexes. In comparison to blood samples obtained from normal donors, patient plasma and serum demonstrated reduced binding of a fast-acting plasminogen activator inhibitor to 125I-labeled t-PA. Immunoprecipitation experiments indicated diminished complex formation between type 1 plasminogen activator inhibitor (PAI-1) in patient serum and 125I-labeled t-PA. Low patient PAI-1 activity was confirmed in serum (0.36 U/ml, control 0.87-1.81; n = 3) and in platelet lysates using a functional IRMA to quantitate PAI-1 binding to immobilized t-PA. However, patient serum PAI-1 antigen was within the normal range when analyzed by IRMA (31.8 ng/ml, control 19.6-42.2); this result was confirmed in both serum and platelets by Western blot (n = 3). Mixing experiments using purified PAI-1 as well as patient and control sera did not show evidence for an inhibitor against PAI-1. We conclude that this patient's bleeding diathesis was due to hyperfibrinolysis and defective PAI-1. This patient provides the first demonstration of a link between decreased in vivo PAI-1 activity and disordered hemostasis, and supports a role for PAI-1 in control of vivo fibrinolysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ghosh, A. K., & Vaughan, D. E. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22783 · Cited by 679
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.
Schneiderman, J., Sawdey, M. S., Keeton, M. R., Bordin, G. M., Bernstein, E. F., Dilley, R. B., & Loskutoff, D. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.6998 · Cited by 543
Vaughan, D. E., Lazos, S. A., & Tong, K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117809 · Cited by 530
Sawdey, M. S., & Loskutoff, D. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115440 · Cited by 410
Carmeliet, P., Stassen, J. M., Schoonjans, L., Ream, B., van den Oord, J. J., De Mol, M., Mulligan, R. C., & Collen, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116893 · Cited by 388
Metadata
- Authors
- Schleef, R. R., Higgins, D. L., Pillemer, E., & Levitt, L. J.
- Venue
- Journal of Clinical Investigation
- Published
- 1989-05-01
- Volume
- 83
- Issue
- 5
- Pages
- 1747-1752
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1977887439
- Cited by
- 210
- References
- 0
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. https://app.cochat.ai/papers/10.1172/jci114076
- The paper
- Schleef, R. R., Higgins, D. L., Pillemer, E., & Levitt, L. J. (1989). Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. Journal of Clinical Investigation. https://doi.org/10.1172/jci114076
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.